Frontline Treatments for KRAS G12C-Mutation mNSCLC
Experts review the current frontline treatments for patients with KRAS G12C-mutated NSCLC.
Source: onclive.com
Page 28 - Nsclc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nsclc Today - Breaking & Trending Today
The State of Targeted Therapies in NSCLC
Explore the current landscape of targeted therapies in non-small cell lung cancer, focusing on KRAS G12C mutations, molecular testing, and current treatments.
Source: onclive.com
Multidisciplinary Collaboration and Molecular Testing Are Integral to Treatment Decision-Making in NSCLC
Lyudmila A. Bazhenova, MD, expanded on key considerations when navigating the use of perioperative immunotherapy for patients with or without oncogenically-driven lung cancers, the importance of multidisciplinary collaboration when deciding on a treatment plan, and the need for increased and earlier implementation of biomarker testing in all patients with lung cancer.
Source: onclive.com
Telisotuzumab Vedotin Meets Clinical End Points in LUMINOSITY Trial in Previously Treated NSCLC
Telisotuzumab vedotin produced meaningful response rates and other clinically relevant outcomes in patients with c-Met protein overexpressed, EGFR wild-type, advanced or metastatic nonsquamous non–small cell lung cancer.
Source: onclive.com
Non–Small Cell Lung Cancer: Streamlining Turnaround Times in Biomarker Testing
Expert perspectives on improving turnaround times in genomic testing for lung cancer, covering strategies, challenges, and the significance of liquid biopsy in optimizing patient care.
Source: onclive.com